Ndjeka, N., Campbell, J. R., Meintjes, G., Maartens, G., Schaaf, H. S., Hughes, J., . . . Menzies, D. (2022). Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in South Africa: A retrospective cohort study. The Lancet infectious diseases, 22(7), 1042-1051. https://doi.org/10.1016/S1473-3099(21)00811-2
Citace podle Chicago (17th ed.)Ndjeka, Norbert, et al. "Treatment Outcomes 24 Months After Initiating Short, All-oral Bedaquiline-containing or Injectable-containing Rifampicin-resistant Tuberculosis Treatment Regimens in South Africa: A Retrospective Cohort Study." The Lancet Infectious Diseases 22, no. 7 (2022): 1042-1051. https://doi.org/10.1016/S1473-3099(21)00811-2.
Citace podle MLA (9th ed.)Ndjeka, Norbert, et al. "Treatment Outcomes 24 Months After Initiating Short, All-oral Bedaquiline-containing or Injectable-containing Rifampicin-resistant Tuberculosis Treatment Regimens in South Africa: A Retrospective Cohort Study." The Lancet Infectious Diseases, vol. 22, no. 7, 2022, pp. 1042-1051, https://doi.org/10.1016/S1473-3099(21)00811-2.